PROTECT
2023
Sparsentan in IgA Nephropathy
In 404 patients with IgA nephropathy and proteinuria despite maximal RAS blockade, sparsentan reduced proteinuria compared with irbesartan.
Result
ratio0.5995% CI 0.51-0.69 · P < 0.0001
Also reported: eGFR chronic slope difference 1.1 mL/min/1.73m²/yr (95% CI 0.1–2.1; p=0.037) over 2 years.
- Subtopic
- IgA nephropathy
- Design
- Phase 3 double-blind, active-controlled RCT
- Relevance
- Important: one of several pillars.
- Cited in
- KDIGO 2025 IgA Nephropathy
- Source
- Rovin BH, et al. Lancet. 2023;402(10417):2077-2090.doi 10.1016/S0140-6736(23)00569-X
Discussion & critique
Dual endothelin/angiotensin antagonism; supported accelerated then full FDA approval of Filspari for IgA nephropathy.